Corcept Therapeutics Shares Drop Nearly 11%
Shares of Corcept Therapeutics were slipping after the FDA updated a Complete Response Letter for the company's relacorilant capsules, with the FDA saying that it informed the company "on several occasions" of its concerns about the adequacy of the clinical development program during pre-submission meetings. In the previous CRL, the FDA determined it could not approve the application in its present form. Shares of Corcept were nearly 11% lower in afternoon trading.
